Biontech has received $91.5m in equity funding as part of the extension of a deal to develop a cancer immunotherapy candidate with Sanofi.

The online pharmaceutical distributor has secured $73m in a series C-plus round that follows a Tencent-led round last April.

The genomic testing platform developer has now raised some $140m, eight years after being co-founded in EPFL's Innovation Park by researchers from EMBL, Stanford and Geneva University.

Generation Investment Management has led the Swisscom-backed genomic testing platform developer's latest round, boosting its overall funding to $140m.

Celgene and Evotec have put capital into Exscientia as the Dundee-founded automated drug discovery services provider added Roche to its roster of development partners.

Based on research from the universities of Bristol and Nottingham, Exonate has now raised $9m to develop a topical eye drop for conditions including diabetic macular edema.

Minnesota-founded microbial analysis spinout CoreBiome has been bought by medical diagnostics firm OraSure Technology after raising $1.4m from investors including Minnesota’s Discovery Capital fund.

Autoimmune disease therapy spinout Cabaletta Bio's series B round brought its total to at least $88m allowed the university to pare back its shareholding.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

Medical device developer Ablative Solutions has closed the first tranche of its series D round having secured an undisclosed corporate backer.